Related Experiment Video
Updated: Jul 19, 2026

Tail Vein Transection Bleeding Model in Fully Anesthetized Hemophilia A Mice
Published on: September 30, 2021
Use of rFVIIa in 4 children with Glanzmann thrombasthenia
1Hemophilia and Thrombophilia Center, Rush University Medical Center and Rush Children's Hospital, 1653 West Congress Parkway, Chicago, IL 60612-3833, USA. lvalentino@rush.edu
Inherited deficiencies of platelet surface glycoproteins, such as Glanzmann thrombasthenia (GT), occasionally result in severe bleeding episodes. Platelet transfusion is considered standard therapy for securing hemostasis in subjects with GT when local measures and antifibrinolytic agents are inadequate. We describe 4 case studies which suggest that recombinant activated factor VII may be an effective alternative to platelet transfusion in preventing or controlling bleeding, including surgical bleeding, in patients with GT.
Inherited deficiencies of platelet surface glycoproteins, such as Glanzmann thrombasthenia (GT), occasionally result in severe bleeding episodes. Platelet transfusion is considered standard therapy for securing hemostasis in subjects with GT when local measures and antifibrinolytic agents are inadequate. We describe 4 case studies which suggest that recombinant activated factor VII may be an effective alternative to platelet transfusion in preventing or controlling bleeding, including surgical bleeding, in patients with GT.
Related Concept Videos
Hemodialysis I: Introduction
Venous Thrombosis III: Interprofessional Care
Varicose Veins II: Diagnostic Studies and Interprofessional Care